Unkown Quantity..., page-24

Hi Hoyland, it might surprise you that that Bluebird Bio has been around since 1992. They changed their name in 2010 from Genetix Pharmaceuticals when Third Rock made a $35m investment and made one of their partners Nick Leschley the new CEO. They got earlier VC funding in 2004 of around $13m to take their Beta Thallesemia drug (still in PIII in 2015) to PI/II testing.

Sounds earily similar to BLT. If RA Capital participate in the IPO, I can imagine a management shakeup.